Happy Holidays!

Reviewing some big news from ASH21 concerning DLBCL that has us asking, "the more the change, the more R-CHOP remains the same?" Also, we talk CAR-T (ZUMA-7 & BELINDA), sotorasib, a possible way to predict poor response to ICI (HLA-A*03), and Evusheld as a possible way to protect those patients destined to a poor vaccine response from COVID.

The 2nd episode in our Career Paths series features Dr. Morgan Randolph. She gives great insight into her role as pediatric oncology pharmacist and the choice between a PGY2 in Pediatrics or Oncology for those considering that decision.

Lots of updates to discuss from dasatinib dosing to ICI/TKI sequencing in BRAF-mutated metastatic melanoma to adjuvant chemo in node (+) breast cancer to some FDA approval updates.

Discussing one of the more intriguing studies of the year looking at whether metastatic melanoma survival is effected by what time of day immunotherapy is administered.

Link: https://doi.org/10.1016/S1470-2045(21)00546-5

What is a medical science liaison (MSL) and what do they do? Our 1st episode in a series highlighting different career options for oncology pharmacists featuring Dr. Christan Thomas.

Asciminib is now FDA approved and it's not just another TKI for CML

From IMPOWER 010 to NIFTY to CONFIRM to SOLO, there's lots to discuss on this episode.

Adjuvant atezolizumab for select NSCLC patients now FDA approved.

5-year f/u of olaparib maintenance in mBRCA ovarian cancer smells funny: https://doi.org/10.1016/S1470-2045(21)00531-3

CONFIRM: https://doi.org/10.1016/S1470-2045(21)00471-X

NIFTY: https://doi.org/10.1016/S1470-2045(21)00486-1

Palbociclib-PPI Interaction? https://doi.org/10.1016/j.esmoop.2021.100231

We return to our Landmarks of OncoPharm series to dive deep into an article that provided some of our foundational understanding of how anthracycline cardiotoxicity risk is influenced by rate of administration.

Link: https://pubmed.ncbi.nlm.nih.gov/2910423/

FDA approves 2-years of abemaciclib plus endocrine therapy for high-risk HR+, HER2(-) patients. Quite a bit to discuss about this. Also, FDA expands indications for pembrolizumab (of course) and brexucabtagene autoleucel.

NOTE: A 5cm breast tumor is a T3 lesion, not a T2 as misstated in this episode.